Abstract: The present invention provides a method for treating patients with spinal cord injury by administering germination activated Ganoderma lucidium spores (GASP) to the patients. The GASP are sporoderm-broken. The GASP promote axon regeneration and improve motor neuron survival in the injured spinal cord.

Abstract: The present invention provides a method for fetal protection by orally administering germination activated Ganoderma lucidum spore powder (“GASP”) to pregnant mammals. GASP demonstrates prophylactic effects on fetal damage in pregnant mammals, particularly humans.

Abstract: The present invention provides an external preparation for skin which contains, as a major ingredient, oleaginous substances extracted from sporoderm-broken spores from Ganoderma lucidum. The spores are preferably being treated with germination activation. The oleaginous substances are preferred to be extracted by a supercritical fluid-carbon dioxide (SCF-CO2) method. The oleaginous substances prepared by SCF-CO2 is transparent and odorless. They also demonstrates effects on skin smoothening, wrinkles reduction, aging defiance, inflammation lessening, pigmentation lightening, and irritation alleviation. The external preparation can be a cosmetic or a therapeutic composition.

Abstract: The present invention provides an external preparation for skin which contains, as a major ingredient, oleaginous substances extracted from sporoderm-broken spores from Ganoderma lucidum. The spores are preferably being treated with germination activation. The oleaginous substances are preferred to be extracted by a supercritical fluid-carbon dioxide (SCF-CO2) method. The oleaginous substances prepared by SCF-CO2 is transparent and odorless. They also demonstrates effects on skin smoothening, wrinkles reduction, aging defiance, inflammation lessening, pigmentation lightening, and irritation alleviation. The external preparation can be a cosmetic or a therapeutic composition.

Abstract: The present invention provides a method for preventing/slowing aging and/or reducing menopause symptoms in humans by orally administering an effective amount of germination-activated Ganoderma lucidum spores (GLSs) to humans. The treatment for menopause is especially effective in male patients. GLSs are effective as an antioxidant to reduce free radical damage, particularly by increasing the amount of the reduced form glutathione (GSH) and the superoxide dismutase (SOD) activity. GLSs can also increase testosterone level in blood and improve depression, particularly geriatric depression, in elderly male patients.

Abstract: The present invention provides a method for treating a mammal with immunological disorders, particularly autoimmune disease, and most preferably systemic lupus erythematosus (SLE). The method includes oral administration of germination activated Ganoderma lucidum spores (“GLSs”) to the mammal. Additionally, a corticosteroid, such as prednisolone, can be co-administered with the GLSs to the mammal to achieve synergistic effect of treatment.

Abstract: The present invention provides a method for promoting proliferation and/or differentiation of neural stem cells in a mammal, which comprises orally administering sporoderm-broken germination activated Ganoderma lucidum spores (GASP) to the mammal. The effects of GASP on proliferation and/or differentiation of neural stem cells are particularly prominent in mammals after a spinal cord injury.

Abstract: The present invention provides a method for treating patients with spinal cord injury by administering germination activated Ganoderma lucidium spores (GASP) to the patients. The GASP are sporoderm-broken. The GASP promote axon regeneration and improve motor neuron survival in the injured spinal cord.

Abstract: The present invention provides a method for fetal protection by orally administering germination activated Ganoderma lucidum spore powder (“GASP”) to pregnant mammals. GASP demonstrates prophylactic effects on fetal damage in pregnant mammals, particularly humans.

Abstract: The present invention provides a method for treating a mammal with immunological disorders, particularly autoimmune disease, and most preferably systemic lupus erythematosus (SLE). The method includes oral administration of germination activated Ganoderma lucidum spores (“GLSs”) to the mammal. Additionally, a corticosteroid, such as prednisolone, can be co-administered with the GLSs to the mammal to achieve synergistic effect of treatment.

Abstract: The present invention provides a method for preventing/slowing aging and/or reducing menopause symptoms in humans by orally administering an effective amount of germination-activated Ganoderma lucidum spores (GLSs) to humans. The treatment for menopause is especially effective in male patients. GLSs are effective as an antioxidant to reduce free radical damage, particularly by increasing the amount of the reduced form glutathione (GSH) and the superoxide dismutase (SOD) activity. GLSs can also increase testosterone level in blood and improve depression, particularly geriatric depression, in elderly male patients.